<?xml version="1.0" encoding="utf-8" standalone="yes"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
  <channel>
    <title>Opioid Lawsuits on FinanClub</title>
    <link>https://finan.club/tags/opioid-lawsuits/</link>
    <description>Recent content in Opioid Lawsuits on FinanClub</description>
    <generator>Hugo -- gohugo.io</generator>
    <language>en-us</language>
    <lastBuildDate>Fri, 18 Aug 2023 10:04:51 +0000</lastBuildDate><atom:link href="https://finan.club/tags/opioid-lawsuits/index.xml" rel="self" type="application/rss+xml" />
    <item>
      <title>TEVA</title>
      <link>https://finan.club/us/teva/</link>
      <pubDate>Fri, 18 Aug 2023 10:04:51 +0000</pubDate>
      
      <guid>https://finan.club/us/teva/</guid>
      <description>score:17
Chances: Teva Pharmaceutical&amp;rsquo;s strong second-quarter results and beating earnings and sales estimates are positive indicators. The company&amp;rsquo;s focus on launching biosimilars and brand-name drugs like Ajovy presents growth prospects. Teva&amp;rsquo;s settlement agreement to pay U.S. hospitals and provide naloxone indicates the company&amp;rsquo;s commitment to resolving legal issues.</description>
    </item>
    
  </channel>
</rss>
